Bio-ConneKt Wound Dressing for Treatment of Chronic Leg Wounds: A Pilot Study

NCT ID: NCT02309684

Last Updated: 2014-12-05

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2016-01-31

Brief Summary

The purpose of this study is to assess the performance of the bio-ConneKt™ wound dressing and compare its performance with the standard of care at NFRMC Wound Therapy Services, for the treatment of chronic foot/leg ulcers (DFU/VLU) in a prospective single center open one-arm clinical study.

Conditions

Skin Ulcer

Keywords

Diabetic Foot Ulcer (DFU); Venous Leg Ulcer (VLU)

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Study Population

Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. A full thickness diabetic foot ulcer with a viable wound bed free of necrotic material (grade 1 on Wagner scale) or a venous leg ulcer confirmed with duplex ultrasound

2. The ulcer has been diagnosed/present for greater than 4 weeks duration.

3. Three or fewer ulcers separated by > 3.0 cm distance

4. Post-debridement, the ulcer size must be > 5 sq cm

5. Ankle / brachial index is between 0.7 to 1.2 and or one of the following must be present:

1. transcutaneous partial pressure oxygen (TcPO2) > 30 mmHg at the ankle

2. toe pressure of >40mm Hg or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic)

6. At least 18 years old

7. Able and willing to read and sign a voluntary written informed consent

8. Able and willing to attend scheduled follow-up visits and study related exams

Exclusion Criteria

1. Greater than 30% reduction in wound size (DFU) or 20% reduction in VLU during first week of observation by the investigator

2. Ulcer with exposed tendon or bone

3. Gross clinical infection at the study ulcer site including cellulitis and osteomyelitis

4. Ulcer of a non-diabetic/non-venous pathophysiology (e.g., rheumatoid, radiation-related, and vasculitis related ulcers)

5. Known severe anemia

6. Known serum albumin < 2.5

7. Renal failure requiring dialysis

8. Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV

9. Severe liver disease as defined by the treating physician or patient's primary care physician

10. Malignancy at or near the ulcer site

11. Any condition judged by the investigator that would cause the study to be detrimental to the patient

12. Presence of a hematology, clinical, chemistry or other test obtained within 7 days of screening that is outside the normal range for the laboratory and is determined to be clinically significant by the investigator

13. Received another investigational device or drug within 30 days of Day 0.

14. Radiation therapy, chemotherapy or immunosuppressive therapy within 30 days of enrollment

15. Received another allograft, autograft or xenograft within 30 days of the Day 0/

16. Known allergy to equine derived tissue

17. Alcohol or drug abuse, defined as current medical treatment for substance abuse

18. Pregnant or nursing women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MLM Biologics Inc.,

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elmer Croushore, MD

Role: PRINCIPAL_INVESTIGATOR

NFRMC Wound Therapy Services

Central Contacts

Elmer Croushore, MD

Role: CONTACT

Phone: 352-538-3180

Chandra Nataraj, PhD

Role: CONTACT

Phone: 352-514-4269

Email: cnataraj@mlmbiologics.com

Other Identifiers

MLM1301

Identifier Type: -

Identifier Source: org_study_id